Artiva Biotherapeutics, Inc./$ARTV

1D1W1MYTD1Y5YMAX

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Ticker
$ARTV
Sector
Health
Primary listing
NASDAQ
Employees
115
Headquarters
San Diego, United States
Website
www.artivabio.com

ARTV Metrics

BasicAdvanced
$345M
-
-$3.21
2.18
-

Bulls say / Bears say

AlloNK received FDA Regenerative Medicine Advanced Therapy designation for refractory rheumatoid arthritis, and Artiva plans to initiate an approximately 150-patient randomized Phase 3 trial in the second half of 2026. (Artiva Biotherapeutics)
Artiva reported $349.4 million in cash, cash equivalents and investments as of June 30, 2026, which management expects to fund operations into 2029 and reduce near-term financing risk around the planned registrational program. (Artiva Biotherapeutics)
The program has shown encouraging activity beyond refractory RA: EULAR 2026 presentations covered 31 patients across rheumatoid arthritis, Sjögren disease and systemic sclerosis, while the company highlighted an outpatient-compatible safety profile and deep B-cell depletion. (Artiva Biotherapeutics)
AlloNK’s lead efficacy signal remains early-stage: the company reported a 71% ACR50 response in only five of seven refractory-RA patients with six months of follow-up, while the larger randomized Phase 3 trial has yet to generate confirmatory data. (SEC)
Artiva remains loss-making and its spending is increasing as development advances: second-quarter 2026 R&D expense rose to $21.9 million and net loss widened to $25.0 million from $21.3 million a year earlier. (SEC)
The May 2026 financing materially diluted existing shareholders, with Artiva issuing 23.9 million common shares plus pre-funded warrants for another 2.2 million shares; the company explicitly disclosed that the transaction resulted in dilution. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.